LISATA THERAPEUTICS, INC. — Director's Dealing 2017

Jan 27, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2017-01-25

Reporting Person: Preti Robert A (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-25	Common Stock	F	272	$3.87	Disposed	42870	Direct

Footnotes

F1: Includes 17,518 shares of unvested restricted stock.